Duchenne Community Keeps The Faith After Dual New Product Setback

The DMD community could be forgiven for feeling disheartened by recent setbacks to potential new treatments in the US and EU. Patient power will not be enough to get DMD drugs past regulators but companies and advocacy groups are keeping the faith. Among other things, they hope that better natural history data may help their cause.